vTv Therapeutics Inc.

0.8352+0.0002+0.02%Vol 21.12K1Y Perf -35.27%
Nov 29th, 2022 00:41 DELAYED
BID0.8220 ASK0.8484
Open0.8190 Previous Close0.8350
Pre-Market- After-Market-
 - -%  - -
Target Price
4.17 
Analyst Rating
Strong Buy 1.00
Potential %
402.41 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     37.78
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
44.52 
Earnings Rating
Buy
Market Cap68.05M 
Earnings Date
8th Nov 2022
Alpha0.03 Standard Deviation0.39
Beta-1.55 

Today's Price Range

0.81510.8500

52W Range

0.38201.40

5 Year PE Ratio Range

-5.00-4.70

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
11.30%
1 Month
-5.17%
3 Months
-26.11%
6 Months
64.99%
1 Year
-35.27%
3 Years
-43.96%
5 Years
-80.98%
10 Years
-

TickerPriceChg.Chg.%
VTVT0.83520.00020.02
AAPL141.45-2.7700-1.92
GOOG95.59-0.6600-0.69
MSFT240.05-1.7100-0.71
XOM110.110.30000.27
WFC47.370.38500.82
JNJ175.68-1.6550-0.93
FB196.640.99000.51
GE85.590.12000.14
JPM135.721.37001.02
 
ProfitabilityValueIndustryS&P 500US Markets
-
-1 400.00
-1 395.40
-25 010.10
-78.87
RevenueValueIndustryS&P 500US Markets
2.02M
0.02
-13.56
69.67
Earnings HistoryEstimateReportedSurprise %
Q03 2022-0.05-0.050.00
Q02 2022-0.10-0.0460.00
Q01 2022-0.08-0.10-25.00
Q04 2021-0.08-0.080.00
Q03 2021-0.07-0.0271.43
Q02 2021-0.07-0.0185.71
Q01 2021-0.06-0.09-50.00
Q04 2020-0.060.02133.33
Earnings Per EndEstimateRevision %Trend
12/2022 QR-0.060.00-
12/2022 QR-0.0657.14Positive
12/2022 FY-0.27-12.50Negative
12/2023 FY-0.31-3.33Negative
Next Report Date-
Estimated EPS Next Report-0.04
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume21.12K
Shares Outstanding81.48K
Shares Float40.72M
Trades Count48
Dollar Volume17.40K
Avg. Volume61.12K
Avg. Weekly Volume58.76K
Avg. Monthly Volume54.87K
Avg. Quarterly Volume69.75K

vTv Therapeutics Inc. (NASDAQ: VTVT) stock closed at 0.835 per share at the end of the most recent trading day (a 9.87% change compared to the prior day closing price) with a volume of 74.65K shares and market capitalization of 68.05M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 25 people. vTv Therapeutics Inc. CEO is Stephen L. Holcombe.

The one-year performance of vTv Therapeutics Inc. stock is -35.27%, while year-to-date (YTD) performance is -16.08%. VTVT stock has a five-year performance of -80.98%. Its 52-week range is between 0.382 and 1.4, which gives VTVT stock a 52-week price range ratio of 44.52%

vTv Therapeutics Inc. currently has a PE ratio of -2.50, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 33.72, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -69.10%, a ROC of -% and a ROE of 123.32%. The company’s profit margin is -78.87%, its EBITDA margin is -1 395.40%, and its revenue ttm is $2.02 Million , which makes it $0.02 revenue per share.

Of the last four earnings reports from vTv Therapeutics Inc., there were 1 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.04 for the next earnings report. vTv Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for vTv Therapeutics Inc. is Strong Buy (1), with a target price of $4.17, which is +402.41% compared to the current price. The earnings rating for vTv Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

vTv Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

vTv Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 17.55, ATR14 : 0.08, CCI20 : -81.17, Chaikin Money Flow : -0.22, MACD : -0.03, Money Flow Index : 37.08, ROC : -9.25, RSI : 47.24, STOCH (14,3) : 29.31, STOCH RSI : 1.00, UO : 31.69, Williams %R : -70.69), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of vTv Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

vTv Therapeutics Inc.

vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.

CEO: Stephen L. Holcombe

Telephone: +1 336 841-0300

Address: 3980 Premier Drive, High Point 27265, NC, US

Number of employees: 25

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

63%37%


News

Stocktwits